Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#4506 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. streptozocin-based chemotherapies (STZ-BC) as first-line (1L) treatment for advanced grade 2/3 (G2/G3) pancreatic NETs (pNETs)

Introduction: The NETTER-2 trial showed improved progression-free survival (PFS) with 1L 177Lu-DOTATATE vs. high dose octreotide in advanced G2/G3 pNETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments, such as STZ-BC, hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Navalkissoor S

Authors: Navalkissoor S, Capdevila J, Deshayes E, Gerard L, Srirajaskanthan R,

Keywords: pancreatic neuroendocrine tumour, [177lu]lu-dotatate, streptozocin, 5-fluorouracil, matching adjusted indirect comparison,

#4504 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. CAPTEM as first-line (1L) treatment for advanced grade 3 (G3) gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Introduction: The NETTER-2 trial showed a significant progression-free survival (PFS) benefit with 1L 177Lu-DOTATATE vs. high dose octreotide for patients with advanced G2/G3 GEP-NETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments for patients with G3 GEP-NETs, such as capecitabine + temozolomide (CAPTEM), hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Deshayes E

Authors: Deshayes E, Capdevila J, Gerard L, Navalkissoor S, Srirajaskanthan R,

Keywords: gastroenteropancreatic neuroendocrine tumour, [177lu]lu-dotatate, capecitabine, temozolomide, matching adjusted indirect comparison,

#4440 Efficacy of octreotide in treating advanced gastrointestinal and pancreatic neuroendocrine tumours: A retrospective cohort study

Introduction: Treatment of advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) lacks high-level evidence and remains controversial.

Conference:

Presenting Author: Wang H

Authors: Wang H, Wang Y, Wang C, Wang G, Chi Y,

Keywords: adjuvant therapy, octreotide, gastroenteropancreatic neuroendocrine tumour,

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,